Spyre reports Q3 2026 results, SPY003 data complete IBD monotherapy trio

Spyre Therapeutics reported third quarter 2026 results on November 3, 2026, announcing positive topline induction data for SPY003 from Part A of the Phase 2 SKYLINE trial, completing proof-of-concept for all three monotherapies in inflammatory bowel disease¹. In Part A, SPY001, SPY002, and SPY003 all achieved their respective primary endpoints, with statistically significant reductions in the Robart's Histopathology Index score of 9.2, 10.7, and 10.0 points respectively, and clinical remission rates of 40%, 33%, and 20%¹. SKYLINE Part B is enrolling ahead of schedule, enabling the company to increase enrollment and provide topline induction results for three potential best-in-indication combinations, expected in Q3 2027¹.

The company also reported positive topline results for SPY072 in the rheumatoid arthritis sub-study of the Phase 2 SKYWAY basket trial, though with a magnitude of benefit insufficient to prioritize advancement¹. SPY072 was well-tolerated but did not meet its primary endpoint in the psoriatic arthritis or axial spondyloarthritis SKYWAY sub-studies, and will not be advanced in rheumatic disease¹.

Spyre initiated a new Phase 2 trial, SKYLIGHT, designed to provide clinical proof-of-concept for dual TL1A and IL-17A/F inhibition in hidradenitis suppurativa¹. The company raised over $400 million in gross proceeds from an underwritten public offering in October to fund a pivotal program in HS with SPY072¹. SKYLIGHT topline Week 16 data are planned in late 2027 or early 2028, according to the filing.

On financials, Spyre reported $1.5 billion in pro forma cash, cash equivalents, and marketable securities as of September 30, 2026, with expected runway into the second half of 2029¹. That pro forma figure of $1,467.9 million reflects $378.0 million in net proceeds from the October 2026 public offering and $18.0 million in October 2026 at-the-market sales¹.